PriceTargets.com logo

Disc Medicine - IRON Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $85.80
  • Forecasted Upside: 44.30%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$59.46 As of 11/15/2024 01:00 AM ET
▼ -1.21 (-1.99%)

This chart shows the closing price for IRON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Disc Medicine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRON

Analyst Price Target is $85.80
▲ +44.30% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Disc Medicine in the last 3 months. The average price target is $85.80, with a high forecast of $118.00 and a low forecast of $70.00. The average price target represents a 44.30% upside from the last price of $59.46.

This chart shows the closing price for IRON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Disc Medicine. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024HC WainwrightBoost TargetBuy ➝ Buy$70.00 ➝ $118.00
11/12/2024WedbushReiterated RatingOutperform$75.00 ➝ $83.00
11/5/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$62.00 ➝ $70.00
11/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
11/5/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$85.00
11/4/2024WedbushReiterated RatingOutperform$60.00 ➝ $75.00
11/4/2024Raymond JamesUpgradeOutperform ➝ Strong-Buy$66.00 ➝ $110.00
10/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
10/23/2024Jefferies Financial GroupInitiated CoverageBuy$89.00
10/16/2024ScotiabankInitiated CoverageSector Outperform$62.00
10/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$85.00 ➝ $85.00
9/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$85.00 ➝ $85.00
9/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
8/22/2024Wells Fargo & CompanyInitiated CoverageOverweight$75.00
8/9/2024WedbushReiterated RatingOutperform ➝ Outperform$57.00 ➝ $57.00
7/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
6/17/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$50.00 ➝ $70.00
6/14/2024WedbushReiterated RatingOutperform$43.00 ➝ $57.00
6/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
5/28/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$85.00 ➝ $85.00
5/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$85.00
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00
5/10/2024Raymond JamesBoost TargetOutperform ➝ Outperform$40.00 ➝ $43.00
4/8/2024Stifel NicolausBoost TargetBuy ➝ Buy$71.00 ➝ $73.00
4/2/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$75.00 ➝ $40.00
4/2/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$80.00 ➝ $50.00
4/2/2024Stifel NicolausLower TargetBuy ➝ Buy$104.00 ➝ $71.00
4/1/2024WedbushReiterated RatingOutperform$84.00 ➝ $43.00
4/1/2024Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$75.00 ➝ $40.00
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00
3/21/2024WedbushReiterated RatingOutperform$79.00 ➝ $84.00
2/29/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$70.00 ➝ $80.00
1/2/2024WedbushReiterated RatingOutperform$79.00
12/20/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$85.00
12/19/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$56.00 ➝ $65.00
11/2/2023WedbushReiterated RatingOutperform$79.00
8/14/2023HC WainwrightBoost TargetBuy ➝ Buy$66.00 ➝ $70.00
6/23/2023Stifel NicolausBoost Target$50.00 ➝ $65.00
6/12/2023BMO Capital MarketsBoost Target$40.00 ➝ $70.00
6/9/2023Stifel NicolausBoost Target$40.00 ➝ $50.00
6/9/2023Cantor FitzgeraldBoost Target$45.00 ➝ $65.00
6/9/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$50.00 ➝ $75.00
6/9/2023HC WainwrightBoost Target$55.00 ➝ $66.00
6/7/2023HC WainwrightInitiated CoverageBuy$55.00
5/16/2023Raymond JamesInitiated CoverageOutperform$50.00
4/28/2023Cantor FitzgeraldInitiated CoverageOverweight$45.00
4/24/2023Lifesci CapitalReiterated RatingOutperform
4/20/2023Stifel NicolausInitiated CoverageBuy$37.00
4/20/2023Morgan StanleyInitiated CoverageOverweight$37.00
3/23/2023BMO Capital MarketsInitiated CoverageOutperform$40.00
2/28/2023Leerink PartnersReiterated RatingOutperform$36.00
2/28/2023SVB SecuritiesInitiated CoverageOutperform$36.00
1/3/2023WedbushInitiated CoverageOutperform$30.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 8 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 7 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/18/2024
  • 16 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 19 very positive mentions
  • 37 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 19 very positive mentions
  • 37 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Disc Medicine logo
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $59.46
Low: $58.94
High: $61.15

50 Day Range

MA: $51.20
Low: $44.82
High: $66.57

52 Week Range

Now: $59.46
Low: $25.60
High: $77.60

Volume

271,441 shs

Average Volume

435,620 shs

Market Capitalization

$1.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Disc Medicine?

The following Wall Street research analysts have issued reports on Disc Medicine in the last twelve months: BMO Capital Markets, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Raymond James, Scotiabank, Stifel Nicolaus, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for IRON.

What is the current price target for Disc Medicine?

0 Wall Street analysts have set twelve-month price targets for Disc Medicine in the last year. Their average twelve-month price target is $85.80, suggesting a possible upside of 44.3%. HC Wainwright has the highest price target set, predicting IRON will reach $118.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $70.00 for Disc Medicine in the next year.
View the latest price targets for IRON.

What is the current consensus analyst rating for Disc Medicine?

Disc Medicine currently has 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IRON will outperform the market and that investors should add to their positions of Disc Medicine.
View the latest ratings for IRON.

What other companies compete with Disc Medicine?

Other companies that are similar to Disc Medicine include Ardelyx, Landsea Homes, Puma Biotechnology, Decibel Therapeutics and Quantum-Si. Learn More about companies similar to Disc Medicine.

How do I contact Disc Medicine's investor relations team?

Disc Medicine's physical mailing address is 297 Boston Post Road #248, Wayland MA, 01778. The company's listed phone number is 617-401-4400 and its investor relations email address is [email protected]. The official website for Disc Medicine is www.discmedicine.com. Learn More about contacing Disc Medicine investor relations.